Eddingpharm (688382.SH) plans to launch a 2026 restricted stock incentive plan.

Yifang Bio (688382.SH) disclosed a draft of its 2026 Restricted Stock Incentive Plan, proposing to grant a total of 6,570,981 shares of restricted stock to incentive recipients, representing approximately 1.14% of the company's total share capital as of the date of the plan's announcement. The grant will be made in a single installment with no reserved equity. A total of 184 individuals are covered under the incentive plan, and the grant price is RMB 10.55 per share.

Zhitong FinanceMay 28 07:23 ET

Cathay Haitong: Technological iteration leads the autoimmune 3.0 era, with密集 catalysts in 2026 driving industrial transformation.

The autoimmune drug sector is currently on the verge of a boom in the 3.0 era, with data from the next generation of autoimmune drugs both domestically and internationally being released successively. The path and trends for drug iteration will gradually become clearer.

Zhitong FinanceMay 6 22:51 ET

Yifang Bio: Yifang Bio\'s First Quarter Report for 2026

SZSIApr 28 12:00 ET · Announcements

Yifang Bio\'s First Quarter Report for 2026

SZSIApr 28 12:00 ET · Announcements

Soochow Securities Starts InventisBio at Buy With 39.03 Yuan Price Target

MT NewswiresApr 27 06:00 ET · Ratings

Cathay Pacific Haitong: The billion-dollar autoimmune sector is undergoing a generational shift as multinational corporations (MNCs) accelerate their efforts to secure the next-generation pipeline.

Immunology blockbuster drugs serve as a crucial cornerstone of MNC's existing business; as patents approach expiration, MNCs are accelerating the development of next-generation immunology pipelines.

Zhitong FinanceApr 17 04:37 ET